Aripiprazole Tablet
Product Images NDC 70518-2869

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 70518-2869). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Aripiprazole 15mg 70518 2869 01

Aripiprazole 15 mg oral tablet packaging label showing a quantity of 30 tablets. Label includes NDC number 70518-2869-01, manufacturer Ascend Labs, LLC (Montvale, NJ), and repackager RemedyRepack Inc. Directions advise referring to package insert and storage at 20-25°C with permitted excursions. The label states RX only and reminds to keep medication out of reach of children.*

FDA Label Image

Aripiprazole 15mg 70518 2869 02

Aripiprazole 15 mg tablet packaging label showing a single tablet quantity. The label includes the NDC number 70518-2869-02, manufacturer Ascend Labs, LLC, and repackager RemedyRepack Inc. It also contains usage directions referencing the package insert and storage instructions.*

FDA Label Image

Aripiprazole-fig-16.jpg (Aripiprazole Fig 16)

A Kaplan-Meier curve chart comparing the proportion of relapse over days from randomization between Aripiprazole and placebo groups. The x-axis shows days from randomization up to 182 days, and the y-axis shows the proportion with relapse from 0 to 1. The chart includes numbers of subjects at risk at various time points for both Aripiprazole and placebo groups.*

FDA Label Image

Aripiprazole-fig-17 (Aripiprazole Fig 17)

A Kaplan-Meier curve showing the proportion of subjects with relapse over time comparing Aripiprazole to placebo. The x-axis represents days from randomization, up to 364 days, and the y-axis shows the proportion with relapse from 0 to 1. The graph includes the number of subjects at risk at various time points for both Aripiprazole and placebo groups.*

FDA Label Image

Effects Of Other Drugs On Dehydro-aripiprazole (Aripiprazole Fig10)

A pharmacokinetic chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' illustrating the fold change relative to reference (without interacting drug) for AUC and Cmax in the presence of various inhibitors and other drugs. The chart displays data for CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and other drugs (valproate, lithium, lorazepam) with associated 90% confidence intervals.*

FDA Label Image

Effects Of Aripiprazole On Pharmacokinetics Of Other Drugs (Aripiprazole Fig11)

A forest plot chart illustrating fold change and 90% confidence intervals in pharmacokinetic parameters (AUC, Cmax, and INR) relative to a reference without interacting drug. The chart includes multiple drugs such as dextromethorphan, warfarin (S- and R-), omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, O-desmethylvenlafaxine, and escitalopram, grouped under different CYP enzyme substrates and other categories.*

FDA Label Image

Effects Of Intrinsic Factors On Aripiprazole (Aripiprazole Fig12)

A pharmacokinetic chart titled 'Aripiprazole Fold Change and 90% CI' displaying fold changes in AUC and Cmax for different variables relative to a reference. Variables include CYP2D6 metabolizer status, gender, age groups, hepatic impairment severity, and severe renal impairment, with fold changes shown as points with horizontal 90% confidence intervals on a logarithmic scale ranging from 0.5 to 3.0.*

FDA Label Image

Effects Of Intrinsic Factors On Dehydro-aripiprazole (Aripiprazole Fig13)

A forest plot showing the fold change of Dehydro-Aripiprazole pharmacokinetic parameters AUC and Cmax with 90% confidence intervals. The plot compares changes relative to reference in groups based on CYP2D6 metabolizer status, gender, age, hepatic and renal impairment severity. The x-axis represents change relative to reference from 0.5 to 3.0.*

FDA Label Image

Effects Of Other Drugs On Aripiprazole (Aripiprazole Fig9)

A pharmacokinetic chart titled 'Aripiprazole Fold Change and 90% CI' depicting the fold change in AUC and Cmax of aripiprazole relative to reference when co-administered with various inhibitors and other drugs. Drugs listed include ketoconazole, quinidine, carbamazepine, famotidine, valproate, lithium, and lorazepam. Data points show effects on AUC and Cmax with 90% confidence intervals.*

FDA Label Image

Remedy_label (Remedy Label)

Aripiprazole 15 mg tablet packaging label. The label indicates a quantity of 30 tablets. It is repackaged by RemedyRepack Inc. Directions for use refer to the package insert. The manufacturer is Ascend Labs, LLC, Montvale, NJ. The label includes storage instructions and a QR code.*

FDA Label Image

Aripiprazole Structure (Aripiprazole Fig8)

Chemical structure of the active ingredient Aripiprazole, depicted as a diagram with rings, chlorine atoms, and functional groups consistent with its molecular structure.*

FDA Label Image

Aripiprazole-graph (Aripiprazole Graph)

A Kaplan-Meier curve displaying the proportion of subjects with relapse over days from randomization, comparing Aripiprazole to placebo. The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. The graph includes a table showing the number of subjects at risk at various time points for both Aripiprazole and placebo groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.